Table 2

Clinical characteristics and lung function parameters in different treatment groups

BDP/F extrafine pMDI (n = 53)

BUD/F and FP/S DPI (n = 58)


Male, n (%)

15 (28.3%)

15(25.8%)


Age, years (mean and range)

48 (19-84)

47 (18-86)


Current smokers, n (%)

20 (37.7%)

19 (32.8%)


Allergies, n (%)

40 (75.5%)

41 (70.6%)


Patients using SABA for as needed medication, n (%)

53 (100%)

50 (86.2%)


Patients using BUD/F for as needed medication, n (%)

0 (0%)

8 (13.8%)


Initial diagnosis of mild persistent asthma, n (%)

0 (0%)

0 (0%)


Initial diagnosis of moderate persistent asthma, n (%)

45 (84.9%)

49 (84.5%)


Initial diagnosis of severe persistent asthma, n (%)

8 (15.1%)

9 (15.5%)


FEV1(mean ± SE; % of predicted)

81.71 ± 17.53

79.38 ± 17.71


PEF (mean ± SE; % of predicted)

78.47 ± 19.92

75.34 ± 22.12


FEF 25-75 (mean ± SE; % of predicted)

62.35 ± 26.18

56.52 ± 23.3


MEF 75 (mean ± SE; % of predicted)

71.53 ± 28.38

71.41 ± 29.01


MEF 25 (mean ± SE; % of predicted)

58.2 ± 26.12

53.74 ± 24.23


SABA = short acting beta2-agonist; BDP = beclomethasone dipropionate; BUD = budesonide; FP = fluticasone propionate; F = formoterol; S = salmeterol. #In pMDI group spirometry data were not available in 2 patients.

Müller et al. BMC Pulmonary Medicine 2011 11:40   doi:10.1186/1471-2466-11-40

Open Data